Stephen Tullman, managing partner of a Chester County biopharmaceutical management company, has nothing but going things to say about his days in Big Pharma.
Participating in GlaxoSmithKline’s management trainee program, provided him with exposure to all facets of the drug-development business while spending time in the United States, London and the Phillipines.
“Leaving GSK [to start his first biopharmaceutical company] was a hard for me,” he said. “ I grew up there. They educated me. They were really good to me. It was a phenomenal experience.”
Today, Tullman leads Malvern-based NeXeption, which is in the business of acquiring new drug candidates that are no longer top priorities for pharmaceutical companies. NeXeption forms individual companies to further develop the experimental therapies before seeking buyers to commercialize the products.
Tullman and his company are profiled (and the $686 million man reference is explained) in this week’s print edition of the Philadelphia Business Journal. Read more about this story on PBJ.com
More NBC10.com stories:
